Alessio Aligi Cogoni

Dr. Alessio Aligi Cogoni

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
LBLuca Boni
Luca Boni
AMAndrea Michelotti
Andrea Michelotti
EMEmanuela Magnolfi
Emanuela Magnolfi
ACAlessio Aligi Cogoni
Alessio Aligi Cogoni
TGthe GIM study group
the GIM study group
Background: Although use of gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is an established strategy to protect ovarian function in premenopausal breast cancer patients, no long-term safety data are available, raising some concerns in women with hormone receptor–positive disease. There are controversial data on its fertility preservation potential. Methods: The Prevention of Menopause Induced by Chemotherapy: a Study in Early Breast Cancer Patients—Gruppo Italiano Mammella 6 (PROMISE-GIM6) trial is a multicenter, randomized, open-label, phase III superiority trial conducted at 16 Italian centers from October 2003 to January 2008. Eligible patients were randomly assigned to (neo)adjuvant chemotherapy alone (control arm) or combined with the GnRHa triptorelin (GnRHa arm). The primary planned endpoint was incidence of chemotherapy-induced premature ovarian insufficiency. Post hoc endpoints were disease-free survival (DFS), overall survival (OS), and post-treatment pregnancies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Results: Of 281 randomly assigned patients, 80.4% had hormone receptor–positive breast cancer. Median follow-up was 12.4 years (interquartile range = 11.3-13.2 years). No differences in 12-year DFS (65.7% [95% CI = 57.0% to 73.1%] in the GnRHa arm vs 69.2% [95% CI = 60.3% to 76.5%] in the control arm; HR = 1.16, 95% CI = 0.76 to 1.77) or in 12-year OS (81.2% [95% CI = 73.6% to 86.8%] in the GnRHa arm vs 81.3% [95% CI = 73.1% to 87.2%] in the control arm; HR = 1.17, 95% CI = 0.67 to 2.03) were observed. In patients with hormone receptor–positive disease, the hazard ratio was 1.02 (95% CI = 0.63 to 1.63) for DFS and 1.12 (95% CI = 0.59 to 2.11) for OS. In the GnRHa and control arms, 9 and 4 patients had a posttreatment pregnancy, respectively (HR = 2.14, 95% CI = 0.66 to 6.92). Conclusions: Final analysis of the PROMISE-GIM6 trial provides reassuring results on the safety of GnRHa use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer, including those with hormone receptor–positive disease.

10 April 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CPCarmine Pinto
Carmine Pinto
Armando OrlandiArmando Orlandi
Armando Orlandi
NNNicola Normanno
Nicola Normanno
EMEvaristo Maiello
Evaristo Maiello
MCMaria Alessandra Calegari
Maria Alessandra Calegari
CBCarlo Barone
Carlo Barone
PURPOSE: The intensity of anti-EGFR–based first-line therapy for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A de-escalation strategy with anti-EGFR monotherapy represents a potential option to maintain efficacy while reducing cytotoxicity. METHODS: In this multicenter, open-label, phase III trial, patients with untreated RAS/BRAF wt mCRC were randomly assigned to receive either fluorouracil, leucovorin, and irinotecan/cetuximab (FOLFIRI/Cet) until disease progression (arm A) or FOLFIRI/Cet for eight cycles followed by Cet alone (arm B). The coprimary end points were a noninferior progression-free survival (PFS) in the modified per-protocol (mPP) population (>eight cycles) and a lower incidence of grade (G) 3-4 adverse events (AEs) for arm B compared with arm A. RESULTS: Overall, 606 patients were randomly assigned, with 300 assigned to arm A and 306 to arm B. The median follow-up was 22.3 months. In the mPP population, 291 events occurred with a PFS of 10 versus 12.2 months for arms B and A, respectively ( P of noninferiority = .43). In the intention-to-treatment (ITT, ≥one cycle) population, 503 events occurred with a PFS of 9 versus 10.7 months ( P = .39). The overall survival was 35.7 versus 30.7 months ( P = .119) and 31.0 versus 25.2 months ( P = .32) in the mPP and ITT population, respectively. Arm B had lower G3-4 AEs during the maintenance period than arm A (20.2% v 35.1%). CONCLUSION: The ERMES study did not demonstrate noninferiority of maintenance with Cet alone. Despite a more favorable safety profile, maintenance with single-agent Cet after induction with FOLFIRI/Cet cannot be recommended for all patients but could represent an option in selected cases.

17 November 2026 in Medicina
Verified
Journal Article
Open access
PDF file
DCDonatella Coradduzza
Donatella Coradduzza
SMSerenella Medici
Serenella Medici
ACAlessio Aligi Cogoni
Alessio Aligi Cogoni
Ciriaco CarruCiriaco Carru
Ciriaco Carru
Andrea AngiusAndrea Angius
Andrea Angius
Maria Rosaria De MiglioMaria Rosaria De Miglio
Maria Rosaria De Miglio
Background/Objectives: Resistance to cancer therapy is attributed to the tumour microenvironment, not to tumour-cell genotype alone. Pyroptosis, the gasdermin-executed lytic death programme triggered mainly by NLRP3, is oncosuppressive in one compartment and resistance-promoting in another. We resolve that divergence by compartment and place brain-derived neurotrophic factor (BDNF) upstream. Methods: Narrative, mechanism-oriented review. Four queries covering the sensor, pyroptotic execution, malignancy and BDNF were screened on title and abstract; retained sources measured at least one step of the cascade, and claims were graded. Results: Acute activation in neoplastic cells releases damage-associated molecular patterns and supports immunogenic cell death, whereas chronic sublytic activation in M2-polarised tumour-associated macrophages sustains interleukin-1β/18 signalling, regulatory T-cell and myeloid-derived suppressor cell expansion, angiogenesis and checkpoint-blockade failure. BDNF restrains inflammasome activation in non-neoplastic systems through nuclear factor-κB priming, mitophagy, KLF2-dependent restraint of hexokinase 1, membrane repair and necroptosis crosstalk; no study has measured BDNF, NLRP3 and pyroptotic execution together in a tumour. Conclusions: We propose that BDNF may set this threshold in tumours, and a four-type classification by BDNF and NLRP3 status to organise experiment, not treatment. It makes compartment, duration and repair capacity, not the pathway's presence, decide whether pyroptotic signalling favours or defeats therapy, and specifies what would falsify it.

10 August 2026 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
DCD. Ciardiello
D. Ciardiello
GMG. Martini
G. Martini
FPF. Pietrantonio
F. Pietrantonio
AAA. Avallone
A. Avallone
SPS. Pisconti
S. Pisconti
SNS. Napolitano
S. Napolitano